Literature DB >> 22583608

[18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer.

Koichi Yasuda1, Rikiya Onimaru, Shozo Okamoto, Tohru Shiga, Norio Katoh, Kazuhiko Tsuchiya, Ryusuke Suzuki, Wataru Takeuchi, Yuji Kuge, Nagara Tamaki, Hiroki Shirato.   

Abstract

PURPOSE: The impact of a new type of positron emission tomography (New PET) with semiconductor detectors using 18F-labeled fluoromisonidazole (FMISO)-guided intensity modulated radiation therapy (IMRT) was compared with a state-of-the-art PET/computed tomography (PET/CT) system in nasopharyngeal cancer (NPC) patients. METHODS AND MATERIALS: Twenty-four patients with non-NPC malignant tumors (control group) and 16 patients with NPC were subjected to FMISO-PET. The threshold of the tumor-to-muscle (T/M) ratio in each PET scan was calculated. The hypoxic volume within the gross tumor volume (GTVh) was determined using each PET (NewPETGTVh and PET/CTGTVh, respectively). Dose escalation IMRT plans prescribing 84 Gy to each GTVh were carried out.
RESULTS: The threshold of the T/M ratio was 1.35 for New PET and 1.23 for PET/CT. The mean volume of NewPETGTVh was significantly smaller than that of PET/CTGTVh (1.5±1.6 cc vs 4.7±4.6 cc, respectively; P=.0020). The dose escalation IMRT plans using New PET were superior in dose distribution to those using PET/CT. Dose escalation was possible in all 10 New PET-guided plans but not in 1 PET/CT-guided plan, because the threshold dose to the brainstem was exceeded.
CONCLUSIONS: New PET was found to be useful for accurate dose escalation in FMISO-guided IMRT for patients with NPC.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22583608     DOI: 10.1016/j.ijrobp.2012.03.029

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.

Authors:  Takuya Toyonaga; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Osamu Manabe; Shiro Watanabe; Shunsuke Terasaka; Hiroyuki Kobayashi; Naoya Hattori; Tohru Shiga; Yuji Kuge; Shinya Tanaka; Yoichi M Ito; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-18       Impact factor: 9.236

2.  (18)F-misonidazole PET imaging of hypoxia in micrometastases and macroscopic xenografts of human non-small cell lung cancer: a correlation with autoradiography and histological findings.

Authors:  Tao Huang; A Cahid Civelek; Huaiyu Zheng; Chin K Ng; Xiaoxian Duan; Junling Li; Gregory C Postel; Baozhong Shen; Xiao-Feng Li
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-03-08

Review 3.  Tumor hypoxia: a new PET imaging biomarker in clinical oncology.

Authors:  Nagara Tamaki; Kenji Hirata
Journal:  Int J Clin Oncol       Date:  2015-11-14       Impact factor: 3.402

4.  The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.

Authors:  Shozo Okamoto; Tohru Shiga; Koichi Yasuda; Shiro Watanabe; Kenji Hirata; Ken-Ichi Nishijima; Keiichi Magota; Katsuhiko Kasai; Rikiya Onimaru; Kazuhiko Tuchiya; Yuji Kuge; Hiroki Shirato; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-01       Impact factor: 9.236

5.  Local relapse of nasopharyngeal cancer and Voxel-based analysis of FMISO uptake using PET with semiconductor detectors.

Authors:  Yukiko Nishikawa; Koichi Yasuda; Shozo Okamoto; Yoichi M Ito; Rikiya Onimaru; Tohru Shiga; Kazuhiko Tsuchiya; Shiro Watanabe; Wataru Takeuchi; Yuji Kuge; Hao Peng; Nagara Tamaki; Hiroki Shirato
Journal:  Radiat Oncol       Date:  2017-09-06       Impact factor: 3.481

6.  Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT.

Authors:  Chowdhury Nusrat Fatema; Songji Zhao; Yan Zhao; Wenwen Yu; Ken-ichi Nishijima; Koichi Yasuda; Yoshimasa Kitagawa; Nagara Tamaki; Yuji Kuge
Journal:  BMC Cancer       Date:  2014-09-22       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.